John Comisi says treating sleep apnea may help the mouth while the drugs could reduce saliva, and he urges dentists to watch gums and cavities.
Recap by typeshit. Full story at Augusta University.
Pratt, a psychology professor who studies the circuits behind food motivation, walks through what neuroscience shows about these drugs.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
He argues speed is the wrong first question, saying the drugs don't do the work on their own. A short take with no new data.
The telehealth company's press release says the price stays flat as doses rise, billed $375 per quarter. Compounded versions are not FDA approved, the release notes.
Loading…